BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
See today's BioWorld
Home
» Through Beigene, Amgen helps awaken the sleeping giant; $2.7B cash investment
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Through Beigene, Amgen helps awaken the sleeping giant; $2.7B cash investment
Nov. 4, 2019
By
Lee Landenberger
and
Elise Mak
No Comments
When the time was right to make a powerful Western biotech welcome in China,
Beigene Ltd.
was ready when
Amgen Inc.
came calling. Its massive $2.7 billion cash equity investment in Beigene buys Amgen an oncology footprint in China.
BioWorld
Deals and M&A